Delonix Bioworks

Startup

Delonix Bioworks specializes in developing next-generation genetically engineered bacterial vaccines. Founded by pioneers in synthetic biology and vaccinology, we have built comprehensive genome editing toolkits for over 16 pathogens and established multiple proprietary vaccine technology platforms.

Our flagship OMV Plus platform is a state-of-the-art genetically engineered technology that generates OMV vaccine candidates with enhanced efficacy and safety profiles. It enables scalable, cost-effective production and significantly accelerates development timelines—taking candidates from discovery to IND application in just 18 months. This platform empowers our Meningococcal Group B vaccine candidate, which shows best-in-class profiles and is approaching IND submission in 2025.

We offer flexible partnership models, including product out-licensing, co-development, and contracted services. Partner with us to accelerate innovative bacterial vaccine development.

Pipeline open for licensing-out or NewCo opportunities

- Meningococcal B OMV vaccine (best-in-class profile, expect IND in 2025)

- Neisseria gonorrhea OMV vaccine (potential best-in-coverage profile, expect IND in 2026)

- Pertussis OMV vaccines (improve protection against immune escape strains and prevent transmission, expect IND in 2026)

We also welcome co-development using our one-stop vaccine development capabilities for:

- S. aureus, K. pneumoniae, P. aeruginosa and TB, or any pathogens nominated by you.

website